New drug IBI3003 enters first human trials for Hard-to-Treat multiple myeloma
NCT ID NCT07336472
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called IBI3003 in about 360 people with multiple myeloma that has returned or no longer responds to standard treatments. The study has two parts: first, finding the safest and most effective dose, and then testing how well it works. Participants will receive the drug for up to 24 months or until their disease gets worse or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI3003 (a drug given intravenously)
What this could lead to
If successful, this could provide a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early first-in-human study, so the drug may not work or could cause serious side effects. It is also not a cure, as treatment continues indefinitely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••